Hyqvia® (immune globulin infusion 10% [human] with recombinant human hyaluronidase) – Expanded Indication
April 11, 2023 - Takeda announced the FDA approval of Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase), for the treatment of primary immunodeficiency (PI) in adults and pediatric patients two years of age and older. This includes, but is not limited to, common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Top